In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Bicara Therapeutics Inc (NASDAQ: BCAX) closed at $14.74 down -7.76% from its previous closing price of $15.98. In other words, the price has decreased by -$7.76 from its previous closing price. On the day, 0.63 million shares were traded. BCAX stock price reached its highest trading level at $16.105 during the session, while it also had its lowest trading level at $14.5.
Ratios:
For a deeper understanding of Bicara Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.80 and its Current Ratio is at 25.80. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On May 23, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $8.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $8.Wells Fargo initiated its Underweight rating on April 17, 2025, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 15 ’25 when Cohlhepp Ryan sold 12,500 shares for $18.16 per share. The transaction valued at 226,942 led to the insider holds 198,141 shares of the business.
Mazumdar Claire bought 24,103 shares of BCAX for $453,761 on Oct 16 ’25. On Oct 15 ’25, another insider, Mazumdar Claire, who serves as the Chief Executive Officer of the company, sold 13,289 shares for $18.84 each. As a result, the insider received 250,391 and left with 309,892 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAX now has a Market Capitalization of 804987904 and an Enterprise Value of 369888288.
Stock Price History:
The Beta on a monthly basis for BCAX is -0.74, which has changed by -0.32772404 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, BCAX has reached a high of $28.09, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is 1.63%, while the 200-Day Moving Average is calculated to be 16.79%.
Shares Statistics:
For the past three months, BCAX has traded an average of 525.04K shares per day and 685200 over the past ten days. A total of 54.56M shares are outstanding, with a floating share count of 30.99M. Insiders hold about 43.26% of the company’s shares, while institutions hold 64.05% stake in the company. Shares short for BCAX as of 1760486400 were 5679088 with a Short Ratio of 10.82, compared to 1757894400 on 5669220. Therefore, it implies a Short% of Shares Outstanding of 5679088 and a Short% of Float of 16.259999999999998.
Earnings Estimates
As of right now, 8.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.37 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.91 and -$2.43 for the fiscal current year, implying an average EPS of -$2.22. EPS for the following year is -$2.45, with 8.0 analysts recommending between -$1.88 and -$3.01.
